Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
about
Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanomaCutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the LiteratureCutaneous complications of molecular targeted therapy used in oncologyCutaneous side effects of vemurafenib: a case report and discussion.Drug safety evaluation of vemurafenib in the treatment of melanoma.No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients.Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy.Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.Update on the Epidemiology of Melanoma.Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Metastatic Malignant Melanoma After Initiating Treatment with Vemurafenib.Molecular targeted therapies in metastatic melanoma.Immunotherapy in the management of melanoma: current status.Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.Dermatological adverse events from BRAF inhibitors: a growing problem.Skin toxicity of targeted cancer agents: mechanisms and intervention.Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.Managing the skin toxicities from new melanoma drugs.Cutaneous adverse events during vemurafenib therapy.BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors.Drug-induced eruptive melanocytic nevi.Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.Profile of vemurafenib-induced severe skin toxicities.Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: Protein phosphatase 2A targeting and MAPK cascade activation.Latest approved therapies for metastatic melanoma: what comes next?Dermoscopic clues to diagnose acantholytic dyskeratosis.Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.Multiple palpebral syringomas occurring after initiation of BRAF inhibition therapy in a patient with metastatic melanoma.Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors.Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: a report of two cases.The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma.Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma.Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study.Darier disease-like hyperkeratotic papules and invasive squamous cell carcinoma in a patient with melanoma treated with dabrafenib.Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF (V600) mutation-positive solid tumors: a phase 1 study.Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient.Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors.
P2860
Q26745933-2B4D0AC9-5CF8-461D-AF9F-61B928151A7AQ26752774-016C5AA2-D144-4025-8DA0-2804C5020F8BQ28070095-E7CE7FB4-793C-4A1B-ADDC-74EF57825FBEQ30456779-9D41B7F1-436D-450A-A304-EB7EC2F3914BQ34653547-EA86D126-3735-4CF9-BADF-F40EE2391BF5Q35013602-1E8AD927-B949-4065-A218-D5F30882CE0BQ35569132-57748C05-6D3D-45A9-9F2B-C650986339CFQ35799917-A9EFCDDF-7BBB-476A-93FA-06E91CE693E2Q36748032-6F6C8B59-F6DA-4D69-8753-294C6C1FDD9BQ36871242-2A043797-97E5-43B9-AC2C-74A35B2379B8Q36984179-001029D6-3D47-48A3-8CB4-13612D91B03CQ37054958-C5B767A8-6807-43F9-92AB-7F3284180B56Q37178600-9AFCA9F0-3194-485B-9732-2739AD30FA98Q38086762-C1A605FA-327C-42C7-BEA2-6BE18B4F553CQ38125504-2AE75A3B-9C13-4AC2-8705-81D38C1B184FQ38139282-ABD76A59-9AE9-41B5-AACE-B899BDBA2C0FQ38203019-C71E5339-052D-4AA4-88E1-A8908F2728D5Q38215416-5831AEA5-6CB9-40FB-A8EE-AAF5DAF2B58BQ38227760-FECF94D4-9008-465C-AFCA-C3ECB60EE85AQ38281838-6DF6BB09-7E02-490F-B6FD-2F5370DD2F5DQ38867037-17521604-4077-4D9B-9AA9-6938019C7171Q38948950-A9328E07-E798-407D-A502-36B782B4140CQ38985224-6E857F95-054D-42AD-A2A1-4B1BB63990B6Q39394089-3E427F10-4B40-4205-B6A0-0666C58645A1Q40366752-63D9B90B-A8AE-4741-871C-6597CEBDA0E7Q40579796-02FCEEFE-33AF-40D1-A32D-ABE7693ACAD6Q41206469-2C919AFA-C670-4E69-9030-14494A456F3AQ42035405-B4703F46-5AB5-4CE3-9CCC-653FCCB0333FQ42229504-242135FA-A2E5-4976-BE2E-C350F96738ACQ42355105-9F2FA83D-DEA8-4FF5-9D19-3908E4D07D70Q43702411-E1D7F6D8-E0AF-49F2-934C-7591654A77B5Q46887584-17F42157-26C4-45FF-AF45-662B28352189Q47549324-D6302499-011B-4940-A712-BBC520E959A6Q47835896-378ADE29-8A7E-419F-AD62-C6B1888E4F66Q48126633-97B49175-1E37-42FB-B7FF-7A474EC4F367Q48289802-6541F879-A14A-41BF-83DA-5A0C0E11DCAFQ50209952-BAD6140D-06F7-41C1-BAA7-035A21622FC5Q51349578-E2FAC302-2BFC-4767-A3AF-EDCB0C7994C3Q54263364-EC8C9927-D0C8-4D8F-97EE-65261A4A47F2Q54302909-90D7AE4C-44F9-4F5F-A8F8-DF85D212CB64
P2860
Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@ast
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@en
type
label
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@ast
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@en
prefLabel
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@ast
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@en
P2093
P2860
P1476
Diverse cutaneous side effects ...... py: a clinicopathologic study.
@en
P2093
Christopher J Miller
Emily Y Chu
John T Seykora
Karolyn A Wanat
Leslie A Fecher
Lydia R Giles
Lynn M Schuchter
Marcia S Brose
Misha Rosenbach
Ravi K Amaravadi
P2860
P304
P356
10.1016/J.JAAD.2012.04.008
P407
P577
2012-05-18T00:00:00Z